TURKU, FINLAND - 05/30/2017 (PRESS RELEASE JET)
Medicortex Finland Oy- a clinical-stage biomedicine firm engaged in the development of effective diagnostics and therapies for traumatic brain injury (TBI) and neurodegenerative diseases, today announces the appointment of Mr. Tom Palenius as a member of the Company’s Board, effective immediately.
“Mr. Palenius is a well-respected and seasoned healthcare and technology executive with near thirty years of experience in developing new biomedical technologies in Finland and the EU,” said Dr. Adrian Harel, Chairman of the Board. “We are delighted to welcome him to the Board and look forward to his invaluable perspective and contributions towards establishing strategic partnerships and realizing the commercialization of the Company’s dual technology platforms.”
Mr. Palenius has before served as the CEO of Abacus Diagnostica Oy and he has had several key positions in companies that develop and finance businesses in life sciences. Mr. Palenius has a MSc degree at the Åbo Akademi University in Turku and he has performed a significant amount of complementary education in management, financials and marketing.
“I am honored to join the experienced team at Medicortex who seeks to turn head injury diagnostic and treatment into clinical benefits serving a large patient population” comments Mr. Palenius, and continues that “I’m looking forward to being a part of this important stage of the Company’s growth and success.”
Dr. Adrian Harel will continue as the Chairman of the Board and Dr. Mårten Kvist as the member of the Board.
Medicortex has a crowdfunding campaign ongoing in order to fund the next clinical trial of its brain injury biomarker diagnostic test kit. The public is invited to support the development at www.invesdor.com/medicortex.
Dr. Adrian Harel - CEO
Medicortex Finland Oy
Itäinen Pitkäkatu 4 B, FI-20520 Turku, Finland
Tel. +358 (0) 400 488 817
Fax. +358 (0) 2 251 0100
Medicortex Finland Oy was established in 2014. The company is dedicated to improving the diagnostics and treatment of Traumatic Brain Injury (TBI). Its current focus is on the development of biomarker diagnostics to evaluate the extent and severity of traumatic brain injury and concussion. The second goal is to expand the program to the development of an innovative drug to halt the progression of brain injury.
|person_outline||Full Name:||Dr. Adrian Harel|
|phone||Phone Number:||+358 400 488 817|
|business_center||Company:||Medicortex Finland Oy|
|mail_outline||Email: Send Email|